Marker Therapeutics, Inc.
MRKR
$1.43
$0.021.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.20M | 3.55M | 4.70M | 5.39M | 5.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.20M | 3.55M | 4.70M | 5.39M | 5.70M |
| Cost of Revenue | 11.51M | 11.80M | 14.74M | 15.87M | 14.03M |
| Gross Profit | -8.31M | -8.60M | -10.40M | -10.83M | -8.68M |
| SG&A Expenses | 4.05M | 4.18M | 4.37M | 4.20M | 4.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.55M | 15.98M | 19.11M | 20.07M | 18.42M |
| Operating Income | -12.35M | -12.79M | -14.76M | -15.03M | -13.07M |
| Income Before Tax | -10.91M | -12.18M | -14.25M | -14.56M | -12.73M |
| Income Tax Expenses | -15.20K | -15.20K | 50.00K | 50.00K | 50.00K |
| Earnings from Continuing Operations | -10.90 | -12.16 | -14.30 | -14.61 | -12.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.90M | -12.16M | -14.30M | -14.61M | -12.78M |
| EBIT | -12.35M | -12.79M | -14.76M | -15.03M | -13.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.66 | -0.90 | -1.23 | -1.36 | -1.32 |
| Normalized Basic EPS | -0.41 | -0.53 | -0.74 | -0.82 | -0.80 |
| EPS Diluted | -0.66 | -0.90 | -1.23 | -1.37 | -1.33 |
| Normalized Diluted EPS | -0.41 | -0.53 | -0.74 | -0.82 | -0.80 |
| Average Basic Shares Outstanding | 69.39M | 61.18M | 51.00M | 43.16M | 38.12M |
| Average Diluted Shares Outstanding | 69.39M | 61.18M | 51.00M | 43.16M | 38.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |